Abstract
Chagas and COVID-19 are diseases caused by Trypanosoma cruzi and SARS-CoV-2, respectively. These diseases present very different etiological agents despite showing similarities such as susceptibility/risk factors, pathogen-associated molecular patterns (PAMPs), recognition of glycosaminoglycans, inflammation, vascular leakage hypercoagulability, microthrombosis, and endotheliopathy; all of which suggest, in part, treatments with similar principles. Here, both diseases are compared, focusing mainly on the characteristics related to dysregulated immunothrombosis. Given the in-depth investigation of molecules and mechanisms related to microthrombosis in COVID-19, it is necessary to reconsider a prompt treatment of Chagas disease with oral anticoagulants.
Author supplied keywords
Cite
CITATION STYLE
Pérez-Campos Mayoral, L., Hernández-Huerta, M. T., Papy-García, D., Barritault, D., Zenteno, E., Sánchez Navarro, L. M., … Pérez-Campos, E. (2021). Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation. Molecular and Cellular Biochemistry, 476(10), 3815–3825. https://doi.org/10.1007/s11010-021-04204-3
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.